Treatment of Addiction in Adults with Autism Spectrum Disorder

Part of the Autism and Child Psychopathology Series book series (ACPS)


This chapter examines the relationship between addictive disorders and individuals who have been diagnosed with autism spectrum disorder. Due to scarce research on the topic, very little is known about individuals with ASD and their experiences with various addictions. Due to their decreased likelihood of exploring novel behaviors and introverted nature, it is thought that individuals with ASD are not highly likely to develop substance use disorders; however, because of the different way that dopamine and reward centers of the brain function in individuals with ASD, it is believed that they are more likely to develop addictive disorders and other stimulatory behaviors such as video gaming and watching television. This chapter also explores various treatment options for individuals with comorbid addictive disorders and ASD, including forms of pharmacotherapy and social rehabilitation.


ASD Addiction Addictive disorders SUD Substance abuse Substance dependency Substance disorder Treatment 


  1. Akerele, E., & Levin, F. R. (2007). Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. The American Journal of Addictions, 16(4), 260–268.CrossRefGoogle Scholar
  2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders DSM-IV (4th ed.). Washington, DC: American Psychiatric Association.Google Scholar
  3. American Psychiatric Association. (2013). Diagnostic and statistical manual of psychiatric disorders DSM-V (5th ed.). Arlington, VA: American Psychiatric Association.CrossRefGoogle Scholar
  4. Anthony, W. A. (1993). Recovery from mental illness: The guiding vision of the mental health service system in the 1990s. Psychiatric Rehabilitation Journal, 16(4), 11–23.CrossRefGoogle Scholar
  5. Anton, R. F., Kranzler, H., Breder, C., Marcus, R. N., Carson, W. H., & Han, J. (2008). A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology, 28, 5–12.PubMedCrossRefGoogle Scholar
  6. Arias-Carrión, O., & Pŏppel, E. (2007). Dopamine, learning, and reward-seeking behavior. Acta Neurobiologiae Experimentalis (Wars), 67(4), 481–488.Google Scholar
  7. Baghdadli, A., Gonnier, V., & Aussilloux, C. (2002). Review of psychopharmacological treatments in adolescents and adults with autistic disorders. Encephale, 28(3 Pt 1), 248–254. Review. French.PubMedGoogle Scholar
  8. Banaschewski, T., Poustka, L., & Holtmann, M. (2011). Autism and ADHD across the life span. Differential diagnoses or comorbidity? Nervenarzt, 82(5), 573–580. German.PubMedCrossRefGoogle Scholar
  9. Bauminger, N., & Kasari, C. (2000). Loneliness and friendship in high-functioning children with autism. Child Development, 71(2), 447–456.PubMedCrossRefGoogle Scholar
  10. Beck, A. T., Wright, F. D., Newman, C. F., & Liese, B. S. (1993). Cognitive therapy of substance abuse. New York: Guilford Press.Google Scholar
  11. Bien, T. H., Miller, W. R., & Tonigan, J. S. (1993). Brief interventions for alcohol problems: A review. Addiction, 88, 315–335.PubMedCrossRefGoogle Scholar
  12. Brunetti, M., Di Tizio, L., Dezi, S., Pozzi, G., Grandinetti, P., & Martinotti, G. (2012). Aripiprazole, alcohol and substance abuse: A review. European Review for Medical and Pharmacological Sciences, 16(10), 1346–1354.PubMedGoogle Scholar
  13. Callaghan, R. C., Veldhuizen, S., Jeysingh, T., Orlan, C., Graham, C., Kakouris, G., et al. (2013). Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. Journal of Psychiatric Research, 48(1), 102–110.PubMedCrossRefGoogle Scholar
  14. Carminati, G. G., Deriaz, N., & Bertschy, G. (2006). Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Progress in Neuropsychopharmacology and Biological Psychiatry, 30(2), 312–315.CrossRefGoogle Scholar
  15. Carminati, G. G., Gerber, F., Darbellay, B., Kosel, M. M., Deriaz, N., Chabert, J., et al. (2016). Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuropsychopharmacology and Biological Psychiatry, 65, 85–95.CrossRefGoogle Scholar
  16. Clarke, T., Tickle, A., & Gillott, A. (2016). Substance use disorder in Asperger syndrome: An investigation into the development and maintenance of substance use disorder by individuals with a diagnosis of Asperger syndrome. The International Journal on Drug Policy, 27, 154–163.PubMedCrossRefGoogle Scholar
  17. Compton, W. M., Thomas, Y. F., Stinson, F. S., & Grant, B. F. (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 64(5), 566–576.PubMedCrossRefGoogle Scholar
  18. Copello, A. G., Velleman, R. D. B., & Templeton, L. J. (2005). Family interventions in the treatment of alcohol and drug problems. Drug and Alcohol Review, 24, 369–385.PubMedCrossRefGoogle Scholar
  19. Crane, L., Lind, S. E., & Bowler, D. M. (2013). Remembering the past and imagining the future in autism spectrum disorder. Memory, 21(2), 157–166.PubMedCrossRefGoogle Scholar
  20. Davidson, L. (2005). Recovery in serious mental illness: A new wine or just a new bottle? Professional Psychology: Research and Practice, 36(5), 480–487.CrossRefGoogle Scholar
  21. Davies, S. P. (2013). Still not clear that smoking cessation drugs do not cause psychiatric symptoms. British Medical Journal, 347, f7065.PubMedCrossRefGoogle Scholar
  22. Dawe, S., Gerada, C., Russell, M. A., & Gray, J. A. (1995). Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology, 117(1), 110–115.PubMedCrossRefGoogle Scholar
  23. De Alwis, D., Agrawal, A., Reiersen, A. M., Constantino, J. N., Henders, A., Martin, N. G., & Lynskey, M. T. (2014). ADHD symptoms, autistic traits, and substance use and misuse in adult Australian twins. Journal of Studies on Alcohol and Drugs, 75(2), 211–221.PubMedPubMedCentralCrossRefGoogle Scholar
  24. De La Garza, R., 2nd, Newton, T. F., & Kalechstein, A. D. (2005). Risperidone diminishes cocaine-induced craving. Psychopharmacology, 178, 347–350.CrossRefGoogle Scholar
  25. Dobson, K. S. (2000). Handbook of cognitive-behavioral therapies (2nd ed.). New York: Guilford Press.Google Scholar
  26. Doyle, C. A., & McDougle, C. J. (2012). Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opinion on Pharmacotherapy, 13(11), 1615–1629.PubMedCrossRefGoogle Scholar
  27. Duarte, C. S., Bordin, I. A., Yazigi, L., & Mooney, J. (2005). Factors associated with stress in mothers of children with autism. Autism, 9, 416–427.PubMedCrossRefGoogle Scholar
  28. Ekman, E., & Hiltunen, A. J. (2015). Modified CBT using visualization for autism Spectrum disorder (ASD), anxiety and avoidance behavior – a quasi-experimental open pilot study. Scandinavian Journal of Psychology, 56(6), 641–648.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Engelhardt, C. R., & Mazurek, M. O. (2014). Video game access, parental rules, and problem behavior: A study of boys with autism spectrum disorder. Autism, 18(5), 529–537.PubMedCrossRefGoogle Scholar
  30. Engelhardt, C. R., Mazurek, M. O., Hilgard, J., Rouder, J. N., & Bartholow, B. D. (2015). Effects of violent-video-game exposure on aggressive behavior, aggressive-thought accessibility, and aggressive affect among adults with and without autism spectrum disorder. Psychological Science, 26(8), 1187–1200.PubMedCrossRefGoogle Scholar
  31. Engelhardt, C. R., Mazurek, M. O., & Sohl, K. (2013). Media use and sleep among boys with autism spectrum disorder, ADHD, or typical development. Pediatrics, 132(6), 1081–1089.PubMedCrossRefGoogle Scholar
  32. Feeney, G. F., Young, R. M., Connor, J. P., Tucker, J., & McPherson, A. (2002). Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: Are short-term treatment outcomes for alcohol dependence improved? The Australian and New Zealand Journal of Psychiatry, 36, 622–628.PubMedCrossRefGoogle Scholar
  33. Feltenstein, M. W., & See, R. E. (2008). The neurocircuitry of addiction: An overview. British Journal of Pharmacology, 154(2), 261–274.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Frye, R. E. (2014). Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Journal of Drug Healthcare and Patient Safety, 6, 69–76.CrossRefGoogle Scholar
  35. Gadke, D. L., McKinney, C., & Oliveros, A. (2016). Autism spectrum disorder symptoms and comorbidity in emerging adults. Child Psychiatry and Human Development, 47(2), 194–201.PubMedCrossRefGoogle Scholar
  36. Gerra, G., Di Petta, G., D'Amore, A., Iannotta, P., Bardicchia, F., Falorni, F., et al. (1985). Endorphin activity in childhood psychosis: Spinal levels of 24 cases. Archives of General Psychiatry, 42, 780–783.CrossRefGoogle Scholar
  37. Ghaziuddin, M., Ghaziuddin, N., & Greden, J. (2002). Depression in persons with autism: Implications for research and clinical care. Journal of Autism and Developmental Disorders, 32, 299–306.PubMedCrossRefGoogle Scholar
  38. Gillberg, I. C., Helles, A., Billstedt, E., & Gillberg, C. (2016). Boys with Asperger syndrome grow up: Psychiatric and neurodevelopmental disorders 20 years after initial diagnosis. Journal of Autism and Developmental Disorders, 46(1), 74–82.PubMedCrossRefGoogle Scholar
  39. Goodman, A. (1990). Addiction: Definition and implications. British Journal of Addiction, 85, 1403–1408.PubMedCrossRefGoogle Scholar
  40. Gould, T. J. (2010). Addiction and cognition. Addiction Science & Clinical Practice, 5(2), 4–14.Google Scholar
  41. Grant, B. F., Harford, T. C., Muthén, B. O., Yi, H. Y., Hasin, D. S., & Stinson, F. S. (2007). DSM-IV alcohol dependence and abuse: Further evidence of validity in the general population. Drug and Alcohol Dependence, 86(2–3), 154–166.PubMedCrossRefGoogle Scholar
  42. Grant, J. E., & Kim, S. W. (2006). Medication management of pathological gambling. Minnesota Medicine, 89, 44–48.PubMedPubMedCentralGoogle Scholar
  43. Graves, S. M., Rafeyan, R., Watts, J., & Napier, T. C. (2012). Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: Evidence from the bench and the bedside. Pharmacology & Therapeutics, 136(3), 343–353.CrossRefGoogle Scholar
  44. Groenman, A. P., Oosterlaan, J., Rommelse, N., Franke, B., Roeyers, H., et al. (2013). Substance use disorders in adolescents with attention deficit hyperactivity disorder: A 4-year follow-up study. Addiction, 108, 1503–1511.PubMedCrossRefGoogle Scholar
  45. Hill, E. L., & Frith, U. (2003). Understanding autism: Insights from mind and brain. Philosophical Transacions of the Royal Society Lond B Biological Sciences, 358(1430), 281–289.CrossRefGoogle Scholar
  46. Hofvander, B., Delorme, R., Chaste, P., Nydén, A., Wentz, E., Ståhlberg, O., et al. (2009). Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. BMC Psychiatry, 10, 9–35.Google Scholar
  47. Houben, K., Havermans, R. C., Nederkoorn, C., & Jansen, A. (2012). Beer à no-go: Learning to stop responding to alcohol cues reduces alcohol intake via reduced affective associations rather than increased response inhibition. Addiction, 107(7), 1280–1287.PubMedCrossRefGoogle Scholar
  48. Houben, K., Nederkoon, C., Wiers, R. W., & Jansen, A. (2011). Resisting temptation: Decreasing alcohol-related affect and drinking behaviour by training response inhibition. Drug and Alcohol Dependence, 116, 132–136.PubMedCrossRefGoogle Scholar
  49. Houben, K., Wiers, R. W., & Jansen, A. (2011). Getting a grip on drinking behavior: Training working memory to reduce alcohol abuse. Psychological Science, 22(7), 986–975.CrossRefGoogle Scholar
  50. Hsia, Y., Wong, A. Y., Murphy, D. G., Simonoff, E., Buitelaar, J. K., & Wong, I. C. (2014). Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): A multinational study. Psychopharmacology, 231(6), 999–1009.PubMedCrossRefGoogle Scholar
  51. Husky, M. M., Mazure, C. M., Paliwal, P., & McKee, S. A. (2008). Gender differences in the comorbidity of smoking behavior and major depression. Drug and Alcohol Dependence, 93(1-2), 176–179.PubMedCrossRefGoogle Scholar
  52. Jarvis, T., Tebbutt, J., & Mattick, R. P. (2005). Treatment approaches for alcohol and drug dependence: An introductory guide (2nd ed.). Chichester, UK: Wiley.CrossRefGoogle Scholar
  53. Jhanjee, S. (2014). Evidence based psychosocial interventions in substance use. Indian Journal of Psychological Medicine, 36(2), 112–118.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Karila, L., Reynaud, M., Aubin, H. J., Rolland, B., Guardia, D., Cottencin, O., & Benyamina, A. (2011). Pharmacological treatments for cocaine dependence: Is there something new? Current Pharmaceutical Design, 17(14), 1359–1368.PubMedCrossRefGoogle Scholar
  55. Karila, L., Zarmdini, R., Petit, A., Lafaye, G., Lowenstein, W., & Reynaud, M. (2014). Cocaine addiction: Current data for the clinician. Presse Médicale, 43(1), 9–17.CrossRefGoogle Scholar
  56. Katusic, S. K., Barbaresi, W. J., Colligan, R. C., Weaver, A. L., Leibson, C. L., & Jacobsen, S. J. (2005). Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: A population-based, birth cohort study. Journal of Child and Adolescent Psychopharmacology, 15, 764–776.PubMedCrossRefGoogle Scholar
  57. Keltner, N. L., Coffeen, H., & Johnson, J. E. (2000). Atypical antipsychotic drugs: Part 1. Perspectives in Psychiatric Care, 36(3), 101–104.PubMedCrossRefGoogle Scholar
  58. Kern, A. M., Akerman, S. C., & Nordstrom, B. R. (2014). Opiate dependence in schizophrenia: Case presentation and literature review. Journal of Dual Diagnosis, 10(1), 52–57.PubMedCrossRefGoogle Scholar
  59. Kim, S. H., Han, D. H., Joo, S. Y., & Min, K. J. (2010). The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Human Psychopharmacology, 25(2), 187–190.PubMedCrossRefGoogle Scholar
  60. Kohls, G., Peltzer, J., Schulte-Rüther, M., Kamp-Becker, I., Remschmidt, H., Herpertz-Dahlmann, B., & Konrad, K. (2011). Atypical brain responses to reward cues in autism as revealed by event-related potentials. Journal of Autism and Developmental Disorders, 41(11), 1523–1533.PubMedCrossRefGoogle Scholar
  61. Kohls, G., Schulte-Rüther, M., Nehrkorn, B., Müller, K., Fink, G. R., Kamp-Becker, I., et al. (2013). Reward system dysfunction in autism spectrum disorders. Social Cognitive and Affective Neuroscience, 8(5), 565–572.PubMedCrossRefGoogle Scholar
  62. Koob, G. F., & Le Moal, M. (2008). Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society Lond B Biological Sciences, 363(1507), 3113–3123.CrossRefGoogle Scholar
  63. Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238.PubMedCrossRefGoogle Scholar
  64. Krentzman, A. R., Robinson, E. A. R., Moore, B. C., Kelly, J. F., Laudet, A. B., White, W. L., et al. (2010). How alcoholics Anonymous (AA) and narcotics Anonymous (NA) work: Cross-disciplinary perspectives. Alcoholism Treatment Quartely, 29(1), 75–84.CrossRefGoogle Scholar
  65. Kronenberg, L. M., Goossens, P. J., van Busschbach, J., van Achterberg, T., & van den Brink, W. (2015). Coping styles in substance use disorder (SUD) patients with and without co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD). BMC Psychiatry, 15, 159.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Kronenberg, L. M., Slager-Visscher, K., Goossens, P. J. J., van den Brink, W., & van Achterberg, T. (2014). Everyday life consequences of substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) in adult patients. BMC Psychiatry, 14, 264.PubMedPubMedCentralCrossRefGoogle Scholar
  67. Kumar, B., Prakash, A., Sewal, R. K., Medhi, B., & Modi, M. (2012). Drug therapy in autism: A present and future perspective. Pharmacological Reports, 64(6), 1291–1304.PubMedCrossRefGoogle Scholar
  68. Lalanne, L., Weiner, L., Trojak, B., Berna, F., & Bertschy, G. (2015). Substance-use disorder in high-functioning autism: clinical and neurocognitive insights from two case reports. BMC Psychiatry, 15(1), 149.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Lalanne, L., Laprevote, V., Danion, J. M., & Bacon, E. (2016). Theoretical reflection on the place of memory and temporal cognitive mechanisms in addictive disorders. Encephale, 42(3), 264–269.PubMedCrossRefGoogle Scholar
  70. Lang, J. P., Bonnewitz, M. L., Kusterer, M., & Lalanne-Tongio, L. (2014). Alcohol consumption in patients with psychiatric disorders: Assessment and treatment. Encephale, 40(4), 301–307. French.PubMedCrossRefGoogle Scholar
  71. Lesouef, N., Bellet, F., Mounier, G., & Beyens, M. N. (2014). Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: A meta-analysis of randomized controlled trials. Thérapie, 69(5), 427–435.PubMedCrossRefGoogle Scholar
  72. Levaux, M. N., Larøi, F., Malmedier, M., Offerlin-Meyer, I., Danion, J. M., & Van der Linden, M. (2012). Rehabilitation of executive functions in a real-life setting: Goal management training applied to a person with schizophrenia. Case Reports in Psychiatry, 2012, 503023.PubMedPubMedCentralCrossRefGoogle Scholar
  73. Levin, F. R., Evans, S. M., Brooks, D. J., & Garawi, F. (2007). Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence, 87, 20–29.PubMedCrossRefGoogle Scholar
  74. Levy, S., Katusic, S. K., Colligan, R. C., Weaver, A. L., Killian, J. M., Voigt, R. G., & Barbaresi, W. J. (2014). Childhood ADHD and risk for substance dependence in adulthood: A longitudinal, population-based study. PloS One, 9(8), e105640.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Li, C. S., Morgan, P. T., Matuskey, D., Abdelghany, O., Luo, X., Chang, J. L., et al. (2010). Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients. Proceedings of theNational Academy of Sciences U S A, 107, 14455–14459.CrossRefGoogle Scholar
  76. Longo, L. P. (2002). Olanzapine for cocaine craving and relapse prevention in 2 patients. Journal of Clinical Psychiatry, 63(7), 595–596.PubMedCrossRefGoogle Scholar
  77. Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013). Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction, 108(2), 275–293.PubMedCrossRefGoogle Scholar
  78. Marazziti, D., Presta, S., Baroni, S., Mungai, F., Piccinni, A., Mucci, F., & Dell’Osso, L. (2015). Nalmefene: A novel drug for an old disorder. Current Medicinal Chemistry, 22(27), 3162–3168.PubMedCrossRefGoogle Scholar
  79. Matson, J. L., & Cervantes, P. E. (2014). Commonly studied comorbid psychopathologies among persons with autism spectrum disorder. Research in Developmental Disabilities, 35, 952–962.PubMedCrossRefGoogle Scholar
  80. Mazurek, M. O., & Engelhardt, C. R. (2013). Video game use in boys with autism spectrum disorder, ADHD, or typical development. Pediatrics, 132(2), 260–266.PubMedCrossRefGoogle Scholar
  81. Mazurek, M. O., & Wenstrup, C. (2013). Television, video game and social media use among children with ASD and typically developing siblings. Journal of Autism and Developmental Disorders, 43(6), 1258–1271.PubMedCrossRefGoogle Scholar
  82. McCormick, P. N., Wilson, V. S., Wilson, A. A., & Remington, G. J. (2013). Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. Pharmacological Research, 70(1), 66–71.PubMedCrossRefGoogle Scholar
  83. Miller, W. R., & Rollnick, S. (2012). Meeting in the middle: motivational interviewing and self-determination theory. International Journal of Behavioral Nutrition and Physical Activity, 9(1), 25.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C. H., & Fazel, S. (2015). Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: Population based cohort study. British Medical Journal, 350, h2388.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Montes, G., & Halterman, J. S. (2007). Psychological functioning and coping among mothers of children with autism: A population-based study. Pediatrics, 119(5), 1040–1046.CrossRefGoogle Scholar
  86. Mulligan, R. C., Reiersen, A. M., & Todorov, A. A. (2014). Attention-deficit/hyperactivity disorder, autistic traits, and substance use among Missouri adolescents. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2(2), 86–92.PubMedPubMedCentralCrossRefGoogle Scholar
  87. O’Malley, S. S., Jaffe, A. J., Chang, G., Schottenfeld, R. S., Meyer, R. E., & Rounsaville, B. (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Archives of General Psychiatry, 49, 881–887.PubMedCrossRefGoogle Scholar
  88. Otero, T. L., Schatz, R. B., Merrill, A. C., & Bellini, S. (2015). Social skills training for youth with autism spectrum disorders: A follow-up. Child and Adolescent Psychiatric Clinics of North America, 24(1), 99–115.PubMedCrossRefGoogle Scholar
  89. Oudman, E., Nijboer, T. C., Postma, A., Wijnia, J. W., & Van der Stigchel, S. (2015). Procedural learning and memory rehabilitation in Korsakoff's syndrome – a review of the literature. Neuropsychology Review, 25(2), 134–148.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., et al. (2013). Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology, 23(5), 337–351.PubMedPubMedCentralCrossRefGoogle Scholar
  91. Pitel, A. L., Rivier, J., Beaunieux, H., Vabret, F., Desgranges, B., & Eustache, F. (2009). Changes in the episodic memory and executive functions of abstinent and relapsed alcoholics over a 6-month period. Alcoholism, Clinical and Experimental Research, 33(3), 490–498.PubMedCrossRefGoogle Scholar
  92. Prendeville, J. A., Prelock, P. A., & Unwin, G. (2006). Peer play interventions to support the social competence of children with autism spectrum disorders. Seminars in Speech and Language, 27(1), 32–46.PubMedCrossRefGoogle Scholar
  93. Procyshyn, R. M., Ihsan, N., & Thompson, D. (2001). A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics. Internal Clinical Psychopharmacology, 16(5), 291–294.CrossRefGoogle Scholar
  94. Ramos, M., Boada, L., Moreno, C., Llorente, C., Romo, J., & Parellada, M. (2013). Attitude and risk of substance use in adolescents diagnosed with Asperger syndrome. Drug and Alcohol Dependence, 133(2), 535–540.PubMedCrossRefGoogle Scholar
  95. Rommelse, N., Langerak, I., van der Meer, J., de Bruijn, Y., Staal, W., Oerlemans, A., & Buitelaar, J. (2015). Intelligence may moderate the cognitive profile of patients with ASD. PloS One, 10(10), e0138698.PubMedPubMedCentralCrossRefGoogle Scholar
  96. Rossignol, D. A. (2009). Novel and emerging treatments for autism spectrum disorders: A systematic review. Annals of Clinical Psychiatry, 21(4), 213–236.PubMedGoogle Scholar
  97. Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2015). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: A systematic review. Journal of Intellectual Disability Research, 59(4), 293–306.PubMedCrossRefGoogle Scholar
  98. Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2015). Are opioid antagonists effective in reducing self-injury in adults with intellectual disability? A systematic review. Journal of Intellectual Disability Research, 59(1), 55–67.PubMedCrossRefGoogle Scholar
  99. Rupp, C. I., Kemmler, G., Kurz, M., Hinterhuber, H., & Fleischhacker, W. W. (2012). Cognitive remediation therapy during treatment for alcohol dependence. Journal of Studies on Alcohol and Drugs, 73(4), 625–634.PubMedCrossRefGoogle Scholar
  100. Salzer, M. S., Mcfadden, L., & Rappaport, J. (1994). Professional views of self help groups. Administration and Policy in Mental Health, 22(2), 85–95.CrossRefGoogle Scholar
  101. San, L., Arranz, B., & Martinez-Raga, J. (2007). Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. European Addiction Research, 13(4), 230–243.PubMedCrossRefGoogle Scholar
  102. Santosh, P. J., Baird, G., Pityaratstian, N., Tavare, E., & Gringras, P. (2006). Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child: Care, Health and Development, 32(5), 575–583.Google Scholar
  103. Santosh, P. J., & Mijovic, A. (2006). Does pervasive developmental disorder protect children and adolescents against drug and alcohol use? European Child & Adolescent Psychiatry, 15, 183–188.CrossRefGoogle Scholar
  104. Scott, L. J., & Dhillon, S. (2008). Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents. CNS Drugs, 22(3), 259–262.PubMedCrossRefGoogle Scholar
  105. Scott-Van Zeeland, A. A., Dapretto, M., Ghahremani, D. G., Poldrack, R. A., & Bookheimer, S. Y. (2010). Reward processing in autism. Autism Research, 3(2), 53–67.PubMedPubMedCentralGoogle Scholar
  106. Seeman, P. (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chemical Neuroscience, 5(1), 24–29.PubMedCrossRefGoogle Scholar
  107. Segobin, S. H., Chételat, G., Le Berre, A. P., Lannuzel, C., Boudehent, C., Vabret, F., et al. (2014). Relationship between brain volumetric changes and interim drinking at six months in alcohol-dependent patients. Alcoholism: Clinical and Experimental Research, 38(3), 739–748.CrossRefGoogle Scholar
  108. Sharma, A., & Shaw, S. R. (2012). Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: A meta-analysis. Journal of Pediatric Health Care, 26(4), 291–299.PubMedCrossRefGoogle Scholar
  109. Sizoo, B., van den Brink, W., Gorissen van Eenige, M., & van der Gaag, R. J. (2009). Personality characteristics of adults with autism spectrum disorders or attention deficit hyperactivity disorder with and without substance use disorders. The Journal of Nervous and Mental Disease, 197(6), 450–454.PubMedCrossRefGoogle Scholar
  110. Sizoo, B., van den Brink, W., Koeter, M., Gorissen van Eenige, M., van Wijngaarden-Cremers, P., & van der Gaag, R. J. (2010). Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: Prevalence, risk factors and functional disability. Drug and Alcohol Dependence, 107(1), 44–50.PubMedCrossRefGoogle Scholar
  111. Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H. J. (2014). Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PloS One, 9(2), e87366.PubMedPubMedCentralCrossRefGoogle Scholar
  112. Smedslund, G., Berg, R. C., Hammerstrøm, K. T., Steiro, A., Leiknes, K. A., Dahl, H. M., et al. (2011). Motivational interviewing for substance abuse. Cochrane Database of Systematic Reviews, 5, CD008063.Google Scholar
  113. Smith, L. E., Greenberg, J. S., & Mailick, M. R. (2012). Adults with autism: Outcomes, family effects, and the multi-family group psychoeducation model. Current Psychiatry Reports, 14(6), 732–738.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Smith, M. D., & Philippen, L. R. (2005). Community integration and supported employment. In D. Zager (Ed.), Autism spectrum disorders: Identification education and treatment (pp. 493–514). Mahwah, NJ: Lawrence Erlbaum Associates.Google Scholar
  115. Soderstrom, H., Rastam, M., & Gillberg, C. (2002). Temperament and character in adults with Asperger syndrome. Autism, 6(3), 287–297.PubMedCrossRefGoogle Scholar
  116. Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2013). Cognitive enhancement as a treatment for drug addictions. Neuropharmacology, 64, 452–463.PubMedCrossRefGoogle Scholar
  117. Stoops, W. W., Lile, J. A., Lofwall, M. R., & Rush, C. R. (2007). The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. The American Journal of Drug and Alcohol Abuse, 33, 769–776.PubMedCrossRefGoogle Scholar
  118. Tinsley, M., Hendrickx, S. (2008). Asperger syndrome and alcohol: Drinking to cope ? Kingsley SJ. London. 2008, 9.Google Scholar
  119. Thoma, P., & Daum, I. (2013). Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings. Psychiatry and Clinical Neurosciences, 67(6), 367–383.PubMedCrossRefGoogle Scholar
  120. Thomas, K. H., Martin, R. M., Davies, N. M., Metcalfe, C., Windmeijer, F., & Gunnell, D. (2013). Smoking cessation treatment and risk of depression, suicide, and self harm in the clinical practice research datalink: Prospective cohort study. British Medical Journal, 347, f5704.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T., & Gunnell, D. (2015). Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ, 350, h1109–h1109.PubMedPubMedCentralCrossRefGoogle Scholar
  122. Torrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012). Psychiatric co-morbidity and substance use disorders: Treatment in parallel systems or in one integrated system? Substance Use & Misuse, 47(8–9), 1005–1014.CrossRefGoogle Scholar
  123. Ung, D., Selles, R., Small, B. J., & Storch, E. A. (2015). A systematic review and meta-analysis of cognitive-behavioral therapy for anxiety in youth with high-functioning autism Spectrum disorders. Child Psychiatry and Human Developement, 46(4), 533–547.CrossRefGoogle Scholar
  124. Upadhyaya, H. P., Rose, K., Wang, W., O’Rourke, K., Sullivan, B., Deas, D., & Brady, K. T. (2005). Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. Journal of Child and Adolescent Psychopharmacology, 15, 799–809.PubMedCrossRefGoogle Scholar
  125. Virués-Ortega, J. (2010). Applied behavior analytic intervention for autism in early childhood: Meta-analysis, meta-regression and dose–response meta-analysis of multiple outcomes. Clinical Psychology Review, 30(4), 387–399.PubMedCrossRefGoogle Scholar
  126. Wallace, G. L., Kenworthy, L., Pugliese, C. E., Popal, H. S., White, E. I., Brodsky, E., & Martin, A. (2015. Epub ahead of print). Real-world executive functions in adults with autism spectrum disorder: Profiles of impairment and associations with adaptive functioning and co-morbid anxiety and depression. Journal of Autism and Developmental Disorders. Google Scholar
  127. Weiner, L., Bruckmann, J., & Bizet, E. (2010). Cognitive remediation therapy of working memory and executive dysfunction in Asperger Syndrome: Premilinary results from single-case studies. Mid-Year Meeting of the International Neuropsychological Society, July the 2nd. Krakow, Poland.Google Scholar
  128. Wiers, R. W., Houben, K., Fadardi, J. S., van Beek, P., Rhemtulla, M., & Cox, W. M. (2015). Alcohol cognitive bias modification training for problem drinkers over the web. Addictive Behaviors, 40, 21–26.PubMedCrossRefGoogle Scholar
  129. Wiers, C. E., Ludwig, V. U., Gladwin, T. E., Park, S. Q., Heinz, A., Wiers, R. W., et al. (2015). Effects of cognitive bias modification training on neural signatures of alcohol approach tendencies in male alcohol-dependent patients. Addiction Biology, 20(5), 990–999.PubMedCrossRefGoogle Scholar
  130. Wijesundera, H., Hanwella, R., & de Silva, V. A. (2014). Antipsychotic medication and tobacco use among outpatients with schizophrenia: A cross-sectional study. Annals of General Psychiatry, 13(1), 7.PubMedPubMedCentralCrossRefGoogle Scholar
  131. Wood, J. J., Ehrenreich-May, J., Alessandri, M., Fujii, C., Renno, P., Laugeson, E., et al. (2015). Cognitive behavioral therapy for early adolescents with autism spectrum disorders and clinical anxiety: A randomized, controlled trial. Behavior Therapy, 46(1), 7–19.PubMedCrossRefGoogle Scholar
  132. Wu, B. J., Chen, H. K., & Lee, S. M. (2013). Do atypical antipsychotics really enhance smoking reduction more than typical ones?: The effects of antipsychotics on smoking reduction in patients with schizophrenia. Journal of Clinical Psychopharmacology, 33(3), 319–328.PubMedCrossRefGoogle Scholar
  133. Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011). A meta-analysis of cognitive remediation for schizophrenia: Methodology and effect sizes. The American Journal of Psychiatry, 168(5), 472–485.PubMedCrossRefGoogle Scholar
  134. Wynn, T., & Brunetti, S. (2009). Compounding naltrexone for the treatment of autism. International Journal of Pharmaceutical Compounding, 13(4), 296–299.PubMedGoogle Scholar
  135. Zhang, L., Tang, J., Dong, Y., Ji, Y., Tao, R., Liang, Z., et al. (2015). Similarities and differences in decision-making impairments between autism Spectrum disorder and schizophrenia. Frontiers in Behavioral Neuroscience, 9, 259.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of PsychiatryStrasbourg University HospitalStrasbourgFrance
  2. 2.Translational Medicine Federation, Medical SchoolStrasbourg UniversityStrasbourgFrance
  3. 3.INSERM 1114Strasbourg University HospitalStrasbourgFrance

Personalised recommendations